Author Archives: gutierrezuzquiza

The hit that came out of our genome-wide CRISPR/Cas9 screen is now published. SYCP3, a meiosis-specific gene not normally expressed in somatic tissue, is frequently upregulated in prostate tumours from patients at advanced stages. We show that it enhances metastasis and modulates the DNA damage response pathway. Led by María Rodrigo-Faus, with Inés del Monte-García,Continue reading “SYCP3 drives prostate cancer metastasis — now out in Scientific Reports”

New collaborative work on the C3G signalling axis: its downregulation enhances stem-like properties in glioblastoma cells by promoting the upregulation of the glycolytic enzyme PKM2. Cueto-Remacha M, Manzano S, Iniesta-González M, et al. C3G downregulation enhances stemness in glioblastoma cells by promoting PKM2 upregulation. International Journal of Biological Sciences. 2026;22(12):6500-6520.

Our continuing collaboration with the group of Hakon Hakonarson at the Children’s Hospital of Philadelphia examines the role of neuroinflammation as a driver of Alzheimer’s disease in people with Down syndrome. Qu HQ, Snorradottir AO, Gutierrez-Uzquiza A, Kao C, March M, Hakonarson H. Neuroinflammation as a driver of Down syndrome-associated Alzheimer’s disease. Brain, Behavior, andContinue reading “Neuroinflammation as a driver of Down syndrome-associated Alzheimer’s disease”

A review on how CRISPR-based genetic screens are being used to take apart the pathways that cancer cells use to survive stress — and what that tells us about where the exploitable vulnerabilities are. Mokhles F, Moosavi MA, Gutierrez-Uzquiza A, Velasco G, Li M, Cordani M. Unraveling stress-adaptation pathways in cancer: functional dissection through CRISPR-basedContinue reading “How CRISPR screens are dissecting stress adaptation in cancer”

Collaborative work demonstrating SLU7, a splicing regulator, as a new target in cancer. Rojo C, Otero A, Elizalde M, et al. Demonstration of SLU7 as a new cancer target. Biomedicine & Pharmacotherapy. 2025 Dec;193:118854.

Hepatocyte-specific deletion of C3G impairs full liver maturation and alters glucose homeostasis — another piece of the C3G story we have been building with the groups of Almudena Porras and Carmen Guerrero. Palao N, Mancebo J, Baquero C, et al. Deletion of C3G in hepatocytes impairs full liver maturation and alters glucose homeostasis. Cell DeathContinue reading “Deleting C3G in hepatocytes impairs liver maturation and alters glucose homeostasis”

The published version of our work on dormancy: stromal TGFβ1 upregulates neuropilin-2 in disseminated tumour cells in the lung, driving their escape from dormancy and the outgrowth of metastasis. Understanding what wakes these cells up is one of the central questions in metastasis. Recalde-Percaz L, de la Guia-Lopez I, Linzoain-Agos P, et al. Neuropilin-2 upregulationContinue reading “Neuropilin-2 and the escape from dormancy of disseminated tumour cells”

We are delighted to see that, building on work performed at the ONCOCRISPR Lab, a new inhibitor with promising antitumour properties has been developed against PRMT7 — the gene our CRISPR/Cas9 screens identified as a driver of metastasis in prostate cancer. It is yet another piece of evidence supporting PRMT7 as a highly relevant therapeuticContinue reading “PRMT7 Inhibitors for the Treatment of Prostate Cancer”

Thanks to our work, a new therapy using an old ally has been tested for an angiopathy that until now was considered incurable. A genuine game-changer for these patients. Snorradottir AO, Gutierrez-Uzquiza A, Bragado P, et al. N-Acetylcysteine for hereditary cystatin C amyloid angiopathy: a nonrandomized clinical trial. JAMA Neurology. 2025 May 1;82(5):486-494.